Structural determinants of A3 adenosine receptor activation: Nucleoside ligands at the agonist/antagonist boundary

Journal of Medicinal Chemistry

Volumn 45, Issue 20, 2002, Pages 4471-4484

  Gao, Zhan Guo ^a   Kim, Soo Kyung ^a   Biadatti, Thibaud ^b   Chen, Wangzhong ^a   Lee, Kyeong ^a   Barak, Dov ^c   Kim, Seong Gon ^a   Johnson, Carl R ^b   Jacobson, Kenneth A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (CARBOXYETHYL)PHENYLETHYLAMINO] 5' N ETHYLCARBOXAMIDOADENOSINE; 2 CHLORINE N 6 (3 IODOBENZYL) DERIVATIVE; 4',5' URONAMIDE DERIVATIVE; 6 N CYCLOPENTYLADENOSINE; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; METHANOCARBA; N 6 (3 IODOBENZYL); N 6 (3 IODOBENZYL) 2 CHLOROADENOSINE; NUCLEOSIDE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; LIGAND BINDING; MUTAGENESIS; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ADENOSINE; ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; EPOXY COMPOUNDS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; LIGANDS; MODELS, MOLECULAR; MUTATION; RADIOLIGAND ASSAY; RATS; RECEPTOR, ADENOSINE A3; RECEPTORS, PURINERGIC P1; RIBOSE; SPIRO COMPOUNDS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037179640     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020211+     Document Type: Article

References (62)

1. Jacobson, K. A.; Knutsen, L. J. S. P1 and P2 purine and pyrimidine receptors. In Purinergic and Pyrimidinergic Signaling I; Handbook of Experimental Pharmacology, Vol. 151/I; Abbracchio, M. P., Williams, M., Eds.; Springer-Verlag: Berlin, Germany, 2001; pp 129-175.
2. Müller, C. E. Adenosine receptor ligands-recent developments part I. Agonists. Curr. Med. Chem. 2000, 7, 1269-1288.
3. 1-adenosine receptor with a comparison to an A2-adenosine receptor regulating coronary blood flow. Biochem. Pharmacol. 1986, 35, 2467-2481.
4. 3-adenosine receptors. J. Med. Chem. 1994, 37, 3614-3621.
5. Lee, K.; Ravi, R. G.; Ji, X.-d.; Marquez, V. E.; Jacobson, K. A. Ring-constrained (N)methanocarba-nucleosides as adenosine receptor agonists: Independent 5′-uronamide and 2′-deoxy modifications. Biorg. Med. Chem. Lett. 2001, 11, 1333-1337.
6. Jacobson, K. A.; Ji, X-d.; Li, A.-H.; Melman, N.; Siddiqui, M. A.; Shin, K.-J.; Marquez, V. E.; Ravi, R. G. Methanocarba Analogues of Purine Nucleosides as Potent and Selective Adenosine Receptor Agonists. J. Med. Chem. 2000, 43, 2196-2203.
7. 1 receptor. J. Med. Chem. 1998, 41, 102-108.
8. 3 receptor. J. Med. Chem. 1999, 42, 1393-1400.
9. 3 receptor, Eur. J. Pharmacol. 2002, 443, 39-42.
10. 3 Adenosine receptor ligands; history and perspectives. Med. Res. Rev. 2000, 20, 103-128.
11. 3 adenosine receptors. J. Med. Chem. 1995, 38, 1720-1735.
12. 3-adenosine receptors by selective adenosine derivatives and xanthine-7-ribosides. Drug Dev. Res. 1998, 44, 97-105.
13. 1 receptor ligands. J. Med. Chem. 2000, 43, 829-842.
14. Zimmerman, D. M.; Leander, J. D. Selective opioid receptor agonists and antagonists: research tools and potential therapeutic agents. J. Med. Chem. 1990, 33, 895-902.
15. Holst, B.; Zoffmann, S.; Elling, CE.; Hjorth, S. A.; Schwartz, T. W. Steric hindrance mutagenesis versus alanine scan in mapping of ligand binding sites in the tachykinin NK1 receptor. Mol. Pharmacol. 1998, 53, 166-175.
16. Robins, M. J.; Hansske, F.; Low, N. H.; Park, J. I. A mild conversion of vicinal diols to alkenes. Efficient transformation of ribonucleosides into 2′-ene and 2′,3′-dideoxynucleosides. Tetrahedron Lett. 1984, 25, 367-370.
17. Hansske, F.; Robins, M. J. Regiospecific and stereoselective conversion of ribonucleosides to 3′-deoxynucleosides. A high yield three-stage synthesis of cordycepin from adenosine. Tetrahedron Lett. 1985, 26, 4295.
18. Russell, A. F.; Greenberg, S.; Moffatt, J. G. Reaction of 2-acyloxyisobutyryl halides with nucleosides. II. Reaction of adenosine. J. Am. Chem. Soc. 1973, 95, 4025.
19. Siddiqi, S. M.; Jacobson, K. A.; Esker, J. L.; Melman, N.; Tiwari, K. N.; Secrist, J. A.; Schneller, S. W.; Cristalli, G.; Johnson, C. A.; Ijzerman, A. P.Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors. J. Med. Chem. 1995, 38, 1174-1188.
20. Johnson, C. R.; Esker, J. L.; Van Zandt, M. C. Chemoenzymic synthesis of 4-substituted riboses. S-(4′-Methyladenosyl)-L-homocysteine. J. Org. Chem. 1994, 59, 5854-5855.
21. Vorbrüggen H.; Ruh-Pohlenz, C. Synthesis of nucleosides. Org. React. 2000, 55, 1-630.
22. 3 adenosine receptor-selective antagonists. Neuropharmacology 1997, 36, 1157-1165
23. 3 adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol. Pharmacol. 2001, 60, 1057-1063.
24. Arunlakshana, O.; Schild, H. O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. Chemother. 1959, 14, 48-58.
25. van der Wenden, E. M.; von Frijtag Drabbe Künzel, J. K.; Mathot, R. A.; Danhof, M.; Ijzerman, A. P.; Soudijn, W. Ribosemodified adenosine analogues as potential partial agonists for the adenosine receptor. J. Med. Chem. 1995, 38, 4000-4006.
26. 6-cyclohexyladenosine: an adenosine derivative with antagonist properties at adenosine receptors. Eur. J. Pharmacol. 1988, 156, 157-160.
27. 1 adenosine receptor with receptor/G protein complexes in rat brain membranes. Mol. Pharmacol. 1996, 49, 915-926.
28. 3 Adenosine Receptors. Bioorg. Med. Chem. Lett. 2002, 12, 501-503.
29. 3 adenosine receptor. J. Biol. Chem. 2002, 277, 19056-19063.
30. 3H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. Mol. Pharmacol. 2000, 57, 968-975.
31. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, T. E.; Yamamoto, M.; Miyano, M. Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor. Science 2000, 289, 739-745.
32. Jacobson, K. A.; Gao, Z. G.; Chen, A.; Barak, D.; Kim, S. A.; Lee, K.; Link, A.; van Rompaey, P.; van Calenbergh, S.; Liang, B. T. Neoceptor Concept Based on Molecular Complementarity in GPCRs: A Mutant Adenosine A3 Receptor with Selectively Enhanced Affinity for Amine-Modified Nucleosides. J. Med. Chem. 2001, 44, 4125-4136.
33. 2a Adenosine Receptor. J. Biol. Chem. 1995, 270, 13987-13997.
34. 2a Adenosine Receptor Are Required for Ligand Recognition. Mol. Pharmacol. 1996, 49, 683-691.
35. 2A Adenosine Receptors Are Required for Ligand Recognition. Mol. Pharmacol. 1996, 50, 512-521.
36. 1-adenosine receptor selectively slows AV conduction in guinea pig hearts. Am. J. Physiol. Heart Circ. Physiol. 2001, 280, H334-H343.
37. 1 receptors. J. Med. Chem. 1996, 39, 1463-1471.
38. 3 receptor. J. Med. Chem. 2002, 45, 420-429.
39. 1 adenosine receptor agonists. Bioorg. Med. Chem. 2002, 10, 1115-1122.
40. 2-adenosine receptors coupled to adenylate cyclase. Biochem. Pharmacol. 1992, 43, 1089-1093.
41. Kenakin, T. P. The Pharmacologic Analysis of Drug-Receptor Interactions; Lippincott-Raven, Philadelphia, New York, 1997.
42. Harden, T. K.; Boyer, J. L.; Dougherty, R. W. Drug analysis based on signaling responses to G-protein-coupled receptors. J. Recept. Signal Transduct. Res. 2001, 2, 167-190.
43. Teller, D. C.; Okada, T.; Behnke, C. A.; Palczewski, K.; Stenkamp, R. E. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-proteincoupled receptors (GPCRs). Biochemistry 2001, 40, 7761-7772.
44. Meng, E. C.; Bourne, H. R. Receptor activation: what does the rhodopsin structure tell us? Trends Pharmacol. Sci. 2001, 22, 587-593.
45. Lu, Z.-L.; Saldanha, J. W.; Hulme, E. C. Seven-transmembrane receptors: crystals clarify. Trends Pharmacol. Sci. 2002, 23, 140-146.
46. Colson, A.-O.; Perlman, J. H.; Jinsi-Parimoo, A.; Nussenzveig, D. R.; Osman, R.; Gershengorn, M. C. A hydrophobic cluster between transmembrane helices 5 and 6 constrains the thyrotropin-releasing hormone receptor in an inactive conformation. Mol. Pharmacol. 1998, 54, 968-978.
47. Ballesteros, J. A.; Shi, L.; Javitch, J. A. Structural mimicry in G protein-coupled receptors: Implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol. 2001, 60, 1-19.
48. 3 adenosine receptor antagonists. J. Med. Chem. 2002, 45, 770-780.
49. Sybyl Molecular Modeling System, version 6.7.1; Tripos Inc., 1969 South Hanley Rd., St. Louis, MO 63144, USA.
50. Halgren, T. A.; MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. J. Comput. Chem. 1999, 20, 730-748.
51. Stewart, J. J. P. MOPAC: A semiempirical molecular orbital program. J. Comput.-Aided Mol. Des. 1990, 4, 1-105.
52. van Rhee, A. M.; Jacobson, K. A. Molecular architecture of G protein-coupled receptors. Drug Dev. Res. 1996, 37, 1-38.
53. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M., Jr.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
54. Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. C. Numerical integration of the Cartesian equations of motion for a system with constraints: Molecular dynamics of n-alkanes. J. Comput. Phys. 1977, 23, 327-333.
55. Cullen, B. R. Use of eukaryotic expression technology in the functional analysis of cloned genes. Methods Enzymol. 1987, 52, 684-704.
56. Nordstedt, C.; Fredholm, B. B. A modification of a proteinbinding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. Anal. Biochem. 1990, 189, 231-234.
57. Post SR.; Ostrom RS.; Insel PA. Biochemical methods for detection and measurement of cyclic AMP and adenylyl cyclase activity. Methods Mol. Biol. 2000, 126, 363-374.
58. 278 in ligand binding and sodium modulation. Biochem. Pharmacol. 2000, 60, 661-668.
59. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
60. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
61. 3 adenosine receptor antagonists. J. Med. Chem. 1999, 42, 3055-3065.
62. Fishman, P.; Madi, L.; Bar-Yehuda, S.; Barer, F.; Del Valle, L.; Khalili, K. Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene 2002, 21, 4060-4064.